The Second Judicial Court, in Reno NV, heard evidence this month in a lawsuit regarding the licensing and marketing rights to metabolic activation therapy (MAT). The hearing is expected to conclude in early July.    ADRI expects to prevail in this case and several others related to this issue.

Please check the NEWS items below for related items.   


Copyright ©2015 Aoki Diabetes Research Institute. ALL RIGHTS RESERVED